I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Christopher Henney Biography and Net Worth

Director of Prothena

Christopher S. Henney, Ph.D., D.Sc., is Vice-Chairman of the Board of Cyclacel Pharmaceuticals, Inc. From 1995 to 2004, Dr. Henney served as Chairman of the Board and Chief Executive Officer of Dendreon Corporation, a biotechnology company that he co-founded. He also co-founded and served as a director and in executive positions at both Immunex Corporation and ICOS Corporation. Dr. Henney was Chairman of the Board of Cascadian Therapeutics, Inc. from 2006 to 2018, where he also served as interim President and Chief Executive Officer for part of 2016, and served as Chairman of the Board of Anthera Pharmaceuticals, Inc. from 2008 to 2018. He is a 2011 inductee to The Biotechnology Hall of Fame. Dr. Henney earned his B.Sc. in medical biochemistry, his Ph.D. in experimental pathology and his D.Sc. for contributions to the field of immunology from the University of Birmingham, England. He has served on our Board since 2013.

What is Christopher S. Henney's net worth?: The estimated net worth of Christopher S. Henney is at least $255,500.00 as of July 12th, 2021. Mr. Henney owns 17,500 shares of Prothena stock worth more than $255,500 as of November 24th. This net worth approximation does not reflect any other assets that Mr. Henney may own. Learn More about Christopher S. Henney's net worth.
How do I contact Christopher S. Henney?: The corporate mailing address for Mr. Henney and other Prothena executives is 77 SIR JOHN ROGERSON`S QUAY BLOCK C GRAND CANAL DOCKLANDS, DUBLIN 2 L2, D02 T804. Prothena can also be reached via phone at (531) 236-2500 and via email at [email protected]. Learn More on Christopher S. Henney's contact information.
Has Christopher S. Henney been buying or selling shares of Prothena?: Christopher S. Henney has not been actively trading shares of Prothena during the last ninety days. Most recently, Christopher S. Henney sold 11,108 shares of the business's stock in a transaction on Wednesday, July 14th. The shares were sold at an average price of $55.46, for a transaction totalling $616,049.68. Following the completion of the sale, the director now directly owns 11,108 shares of the company's stock, valued at $616,049.68. Learn More on Christopher S. Henney's trading history.
Who are Prothena's active insiders?: Prothena's insider roster includes Christopher Henney (Director), Carol Karp (Insider), Gene Kinney (Pres), Michael Malecek (Insider), Tran Nguyen (CFO & Chief Strategy Officer ), Dennis Selkoe (Director), Karin Walker (CAO), and Wagner Zago (Insider). Learn More on Prothena's active insiders.
Are insiders buying or selling shares of Prothena?: During the last twelve months, insiders at the biotechnology company sold shares 3 times. They sold a total of 15,000 shares worth more than $525,950.00. The most recent insider tranaction occured on January, 24th when CAO Karin L. Walker sold 5,000 shares worth more than $170,000.00. Insiders at Prothena own 28.2% of the company. Learn More about insider trades at Prothena.
Information on this page was last updated on 1/24/2024.

Christopher S. Henney Insider Trading History at Prothena

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/14/2021	Sell	11,108	$55.46	$616,049.68	11,108
7/12/2021	Sell	23,892	$55.51	$1,326,244.92	17,500
6/25/2021	Sell	12,000	$47.73	$572,760.00	12,000
9/28/2017	Sell	900	$70.00	$63,000.00	900
11/27/2015	Sell	5,000	$75.00	$375,000.00
10/29/2015	Sell	5,000	$55.00	$275,000.00

Christopher S. Henney Buying and Selling Activity at Prothena

Prothena Company Overview

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

Today's Range

Now: $14.60

$14.03

$15.33

50 Day Range

MA: $17.51

$13.51

$22.02

2 Week Range

Now: $14.60

$13.22

$41.54

Volume

468,844 shs

Average Volume

509,059 shs

Market Capitalization

$785.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.16

I was wrong. Dead wrong.

From Porter & Company | Ad